Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

  title={Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.},
  author={Francisco A. Moreno and Christopher B Wiegand and Elizabeth Keolani Taitano and Pedro L. Delgado},
  journal={The Journal of clinical psychiatry},
  volume={67 11},
BACKGROUND Anecdotal reports suggest that psychedelic agents may relieve symptoms of obsessive-compulsive disorder (OCD). This modified double-blind study investigated the safety, tolerability, and clinical effects of psilocybin, a potent 5-HT(1A) and 5-HT(2A/2C) agonist, in patients with OCD. METHOD Nine subjects with DSM-IV-defined OCD and no other current major psychiatric disorder participated in up to 4 single-dose exposures to psilocybin in doses ranging from sub-hallucinogenic to… 

Figures from this paper

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

This first-of-its-kind trial aims to evaluate the feasibility, safety, and tolerability of psilocybin in the treatment of OCD, provide preliminary evidence on the effects of p silocybin on OCD symptoms, and elucidate neural mechanisms that may mediate psilocrybin’s effects on OCD.

A potential role for psilocybin in the treatment of obsessive-compulsive disorder

  • E. Jacobs
  • Psychology, Biology
    Journal of Psychedelic Studies
  • 2020
Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential.

The therapeutic potential of microdosing psychedelics in depression

  • K. Kuypers
  • Psychology
    Therapeutic advances in psychopharmacology
  • 2020
While it is yet unclear whether psychedelic microdosing is of therapeutic value for depression, the aforementioned effects on selective processes suggest that low doses of psychedelics could play a role in depression by inducing some kind of cognitive flexibility, which might lead to decreased rumination.

Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness

Three empirical studies were conducted based on pooled data from Prof. Vollenweider’s research group at the University Hospital of Psychiatry in Zurich, finding that the effects of psilocybin were generally well tolerated and most subjects described the experience as pleasurable, enriching, and non-threatening.

Acute subjective effects in LSD- and MDMA-assisted psychotherapy

LSD and MDMA are currently used medically in Switzerland mainly in patients with posttraumatic stress disorder and depression in group settings, producing similar acute responses as in research subjects.

New Pharmacotherapeutic Approaches to Obsessive-Compulsive Disorder

Results show that recent developments in the treatment of OCD have been modest and primarily involve evidence for the efficacy of escitalopram and other selective serotonin reuptake inhibitors (SSRIs); augmentation with antipsychotics in treatment-refractory patients and combination treatment with D-cycloserine and cognitive-behavioral therapy has also been effective.

Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.

Patients with OCD responded to a four-day period of administration of metergoline with significantly greater self- and observer-rated anxiety compared with the four- day placebo period, supporting the hypothesis that clomipramine's therapeutic behavioral effects in OCD are mediated via serotonergic mechanisms.

Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study.

Bupropion is not an effective treatment for OCD, but the bimodal distribution of the effect supports the notion that dopamine might be involved in the pathophysiology of OCD.

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.

While the results of this meta-analysis support the superiority of clomipramine, head-to-head, double-blind comparisons of these compounds would be the best test of comparative efficacy and tolerability.

Hallucinogens, serotonin and obsessive-compulsive disorder.

Clinical and preclinical data suggest that activation of 5-HT2 receptors by hallucinogens may lead to acute reduction of, as well as possible longer-lasting beneficial effects on, the symptoms of OCD.

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study

PY affects core dimensions of altered states of consciousness and physiological parameters in a dose-dependent manner and provided no cause for concern that PY is hazardous with respect to somatic health.

Obsessive-compulsive disorder: diagnosis and treatment.

  • W. Goodman
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1999
Guidelines for the use of SSRIs and novel approaches for managing treatment-refractory patients are discussed and effective alternatives include switching to a different SSRI, combining another medication or behavioral therapy with SSRI therapy, and employing novel or experimental drug treatments.

[Treatment of obsessive-compulsive disorder].

Treatment of obsessive compulsive disorder has not changed a lot since 2000 and for several infrequent patients with a "malignant syndrome", functional neuro-surgery using deep brain stimulation might be a safe and hopeful therapeutic technique.

The potential role of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder.

The authors examine the role of the serotonergic system in the modulation or genesis of obsessive compulsive disorder and the potential for the use of the new serotonin (5-HT) reuptake inhibitors in

Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.

It is hypothesized that the mechanism of action of serotonin reuptake inhibitors in obsessive-compulsive disorder may be related to chronic treatment-induced adaptive changes in presynaptic serotonin receptor function and/or indirect influences on dopaminergic function (eg, in the basal ganglia).